mGluR5-PKCγ signaling disrupts the AMPA receptor subunit homeostasis and drives central sensitization in chronic migraine.

Chronic migraine (CM) is linked to changes in brain signaling and pain perception. Researchers studied how certain receptors affect nerve cell behavior in a rat model. They found that a receptor called mGluR5 becomes more active in CM. This increased activity disrupts the balance of AMPA receptors, which are crucial for transmitting pain signals. Specifically, the ratio of two AMPA receptor subunits, GluA1 and GluA2, was altered. When mGluR5 was stimulated, the imbalance worsened, leading to increased pain sensitivity. Conversely, reducing mGluR5 activity helped restore the normal balance of these receptors. This suggests that targeting mGluR5 could be a potential treatment strategy for managing chronic migraine. Understanding these mechanisms may help develop better therapies for those suffering from this painful condition. Clinical relevance: This research indicates that targeting mGluR5 could improve treatments for chronic migraine patients.